Special Discounts for Pupils, Newly Called & Students
Browse Secondhand Online
Online book orders received during the time we are closed will be processed as soon as possible once we re-open on Tuesday.
As usual Credit Cards will not be charged until the order is processed and ready to despatch.
Any non-UK eBook orders placed after 5pm on the Friday 26th May will not be processed until Tuesday 30th May. UK eBook orders will be processed as normal.
The availability of generic and brand-name drugs worldwide is a function of a combination of traditional patent law incentives and emerging 'linkage regulations', which legally tie brand and generic drug approval to drug patents through mandatory litigation for generic firms. Together, these systems of intellectual property law operate to shape the marketplace for brand and generic pharmaceuticals, and thus determine the costs of public and private drug expenditures and access to essential medications in developed and developing nations. The patent monopoly system has been in operation for about 500 years, with early patent laws in Italy and the United Kingdom. By contrast however, the linkage regime has only been in existence for 25 years following passage of the Hatch Waxman Act in the United States in 1984. By 2010, we were witnessing a global spread of the linkage regime stimulated in part by multilateral Free Trade Agreements with the United States and the European Union, which typically oblige participating nations to incorporate linkage provisions in exchange for preferential trade terms. Moreover, there appears to be movement afoot to broaden the concept of linkage outside the drug approval process to include that between patent rights and international trade regulation. Therefore, linkage regulations in respect of pharmaceuticals are emerging as a key driver of public health costs on the global stage. This book provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products. The work focuses on assessment of empirical data pertaining to: firstly, how linkage regulations, which legally the drug patenting to drug approval for both brand-name and generic pharmaceutical firms can be used by sophisticated drug companies to substantially extend monopoly protection on blockbuster drugs; and, secondly, how incentives provided by government to stimulate pharmaceutical innovation can antecedently shape the rate and direction of innovation by firms in a manner opposite to that intended as a result of unintended consequences. Particular attention is given to data relating to trends in the development of 'new' and 'follow-on' drugs and the relation of these trends to the institution of reforms in drug law and patent law intended to stimulate innovation. The book includes empirical research to relate innovation to drug law. A multidisciplinary approach is taken, including the intersection of IP (intellectual property) law, drug law and innovation. The book discusses the impact of government regulation on firm innovation. Brand vs. generic drug wars are also analyzed. The book considers the balance of IP monopoly of private firms with public health mandate. The book reviews the timeline for spread of linkage regulations worldwide and analyses the different linkage regimes in context of the policy goals predating the coming into force of legislation in each jurisdiction.